Cachexia Clinical Trial
Official title:
A Randomized Double-blind (Sponsor Unblind) Placebo Controlled Study in Healthy Subjects to Evaluate: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Repeat Doses of GSK2881078, the Selective Androgen Receptor Modulator With an Open Label Dosing Arm to Evaluate the Effect of CYP3A4 Inhibition on Pharmacokinetics of GSK2881078
GSK2881078 is a selective androgen receptor modulator (SARM) that is being evaluated for effects on muscle growth and strength in subjects with muscle wasting to improve their physical function. Part A of this study will evaluate the safety, efficacy and pharmacokinetics of GSK2881078 in healthy, older men and post-menopausal women who will take daily dosing for 28 days and be followed for a total of 70 days. Part B of this study will characterize the effect of Cytochrome P450 3A4 (CYP3A4) inhibition on the GSK2881078 pharmacokinetics. Part B will only be conducted if safe and efficacious dose is identified in Part A. Part A will include healthy older males and post-menopausal females; and randomize approximately 60 subjects (about 15 per cohort [4 cohorts]) to complete approximately 48 (about 12 per cohort). Part B will enroll one cohort of approximately 15 healthy male subjects to complete approximately 12. The study duration will be approximately 115 days for Part A and 122 days for Part B.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05603585 -
Optimal Protein Supplementation and Early Exercise In Mechanically Ventilated Patients
|
N/A | |
| Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|
||
| Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
| Completed |
NCT01696604 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects
|
Phase 1 | |
| Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
| Completed |
NCT00866970 -
Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia
|
Phase 2 | |
| Active, not recruiting |
NCT00710632 -
Screening to Predict Weight Loss in Patients With Cancer
|
N/A | |
| Completed |
NCT00031785 -
Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer
|
Phase 3 | |
| Withdrawn |
NCT02017925 -
Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation
|
N/A | |
| Recruiting |
NCT01829880 -
Impact of Body Composition on Bisoprolol and Ramipril Pharmacokinetics in Patients With Chronic Heart Failure
|
N/A | |
| Completed |
NCT01692990 -
Study on the Effect of Fish Oil and Appetite
|
Phase 0 | |
| Completed |
NCT01419145 -
A Feasibility Study of Multimodal Exercise/Nutrition/Anti-inflammatory Treatment for Cachexia - the Pre-MENAC Study
|
N/A | |
| Terminated |
NCT00851448 -
Safety, Tolerance and Efficacy of an Oral Nutritional Supplement in Lung Cancer Patients
|
N/A | |
| Completed |
NCT00994669 -
Development of a Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients
|
N/A | |
| Terminated |
NCT00962234 -
Metabolism of Lipids in Advanced Cancer
|
N/A | |
| Completed |
NCT01015274 -
Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients
|
||
| Completed |
NCT00972634 -
Computerized Questionnaires in Assessing Symptoms, Pain, Depression, and Physical Function in Patients With Metastatic and/or Advanced Locoregional Cancer
|
N/A | |
| Terminated |
NCT00535015 -
Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT00558558 -
Haelan and Nutrition in Cancer Patients
|
Phase 2 | |
| Withdrawn |
NCT00163072 -
Pharmacokinetics and Safety of Transdermal Megestrol Acetate
|
Phase 4 |